NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Average Target Price of $48.90 According to Analysts

Key Points

• Analysts maintain a moderately bullish outlook: Twelve firms rate NewAmsterdam Pharma “Moderate Buy,” with nine buys and one strong buy. Their average 12-month price target is $48.90, well above the stock’s reported $20.06 price.
• Shares have weakened and the company remains unprofitable: NAMS trades near its 12-month low of $19.13 and below its 50-day and 200-day moving averages. The latest quarter showed a $0.52-per-share loss, missing estimates, though revenue exceeded expectations.
• Institutional ownership is substantial, while insider activity is mixed: Institutional investors and hedge funds own 89.89% of the stock. The CEO bought 10,000 shares, but insiders sold 176,846 shares worth $4.66 million over the past three months.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $48.90.

NAMS has been the subject of several recent research reports. Royal Bank Of Canada dropped their price target on NewAmsterdam Pharma from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, October 5th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Sunday. HC Wainwright reaffirmed a "buy" rating and set a $52.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. Jefferies Financial Group reiterated a "buy" rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 target price for the company.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $20.06 on Friday. The company's 50 day simple moving average is $22.86 and its 200-day simple moving average is $29.83. The firm has a market capitalization of $2.40 billion, a PE ratio of -9.29 and a beta of 0.10. NewAmsterdam Pharma has a 12 month low of $19.13 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $2.83 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.82 earnings per share for the current year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CEO Michael Davidson purchased 10,000 shares of the business's stock in a transaction on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the acquisition, the chief executive officer owned 792,923 shares of the company's stock, valued at approximately $17,959,705.95. The trade was a 1.28% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johannes Kastelein sold 50,246 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total value of $1,257,657.38. Following the transaction, the insider directly owned 69,302 shares in the company, valued at approximately $1,734,629.06. This represents a 42.03% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 176,846 shares of company stock valued at $4,661,919. Company insiders own 12.74% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently added to or reduced their stakes in NAMS. Bank of America Corp DE lifted its position in NewAmsterdam Pharma by 84.4% during the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company's stock worth $27,115,000 after acquiring an additional 387,698 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock valued at $613,033,000 after acquiring an additional 1,145,128 shares in the last quarter. Squarepoint Ops LLC grew its position in NewAmsterdam Pharma by 113.9% in the second quarter. Squarepoint Ops LLC now owns 92,026 shares of the company's stock valued at $3,119,000 after acquiring an additional 49,005 shares in the last quarter. Stempoint Capital LP grew its position in NewAmsterdam Pharma by 147.1% in the first quarter. Stempoint Capital LP now owns 180,658 shares of the company's stock valued at $5,783,000 after acquiring an additional 107,552 shares in the last quarter. Finally, Maverick Capital Ltd. raised its stake in shares of NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company's stock valued at $69,987,000 after purchasing an additional 292,176 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma NASDAQ: NAMS is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company's primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.